Recent News

• 05.13.2025 - Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
• 05.13.2025 - Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
• 02.28.2025 - Orchard Therapeutics anuncia un acuerdo de reembolso en España
• 02.28.2025 - Orchard Therapeutics Announces Reimbursement Agreement in Spain
• 02.12.2025 - Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
• 02.12.2025 - Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
• 02.03.2025 - Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
• 02.03.2025 - Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
• 10.23.2024 - Orchard Therapeutics Announces Multiple Data Presentations and Publications
• 10.23.2024 - Orchard Therapeutics Announces Multiple Data Presentations and Publications

Recent Filings

• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors